results from tirzepatide SHOCKING Month 2 Tirzepatide outperformed semaglutide weight-loss drug

Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]

It is crucial to note that the prescribing information for both drugs did not disclose any risks associated with similar gastrointestinal events or issue warnings regarding the potential development of gastroparesis

Ultimately, the Cinderella Injection serves as a testament to the lengths to which cosmetic innovation can go, reflecting broader trends in aesthetic medicine in Korea and beyond

In reality, Ozempic isnt actually a weight loss drug, or at least thats not its intended purpose

Individuals with stubborn pigmentation, sensitive skin, or those exposed to high pollution should prioritize oral skin supplements over topical serums